1091599-87-9

Upstream product

• 67-56-1 methanol 
• 1091599-86-8 4-[2-(4-hydroxy-6-methyl-2-oxopyridin-1(2H)-yl)ethyl]benzoic acid 
• 60531-36-4 4-(2-amino-ethyl)-benzoic acid hydrochloride 
• 675-10-5 4-hydroxy-6-methyl-2-pyron 

Downstream Products

• 1091599-88-0 methyl 4-{2-[6-methyl-2-oxo-4-{[(trifluoromethyl)sulfonyl]oxy}pyridin-1(2H)-yl]ethyl}benzoate 
• 1201823-02-0 methyl 4-[2-(3-chloro-4-hydroxy-6-methyl-2-oxopyridin-1(2H)-yl)ethyl]benzoate 
• 1201823-03-1 methyl 4-[2-(3-chloro-6-methyl-2-oxo-5-phenylpyridin-1(2H)-yl)ethyl]benzoate 
• 1201818-66-7 3-{[(4-{2-[3,5-dichloro-2-oxo-6-{[(2S)-2-propylpyrrolidin-1-yl]methyl}pyridin-1(2H)-yl]ethyl}benzoyl)amino]sulfonyl}propyl acetate 
• 1201818-61-2 4-{2-[3,5-dichloro-2-oxo-6-{[(2S)-2-propylpyrrolidin-1-yl]methyl}pyridin-1(2H)-yl]ethyl}-N-[(3-hydroxypropyl)sulfonyl]benzamide 
• 1201818-53-2 4-{2-[3,5-dichloro-6-({[(1R,2R)-2-hydroxycyclopentyl](methyl)amino}methyl)-2-oxopyridin-1(2H)-yl]ethyl}benzoic acid monohydrochloride 
• 1201823-95-1 C₂₇H₃₆Cl₂N₂O₃ 
• 1201823-94-0 C₂₆H₃₄Cl₂N₂O₃ 
• 1201823-86-0 tert-butyl 4-(2-{3,5-dichloro-6-[(6-ethoxy-2,3-dihydro-1H-indol-1-yl)methyl]-2-oxopyridin-1(2H)-yl}ethyl)benzoate 
• 1201818-18-9 4-{2-[3,5-dichloro-6-{[(4-ethylpyridin-2-yl)amino]methyl}-2-oxopyridin-1(2H)-yl]ethyl}benzoic acid mono-trifluoroacetate 
• 1201818-14-5 tert-butyl 4-{2-[3,5-dichloro-2-oxo-6-[(4-propylpiperidin-1-yl)methyl]pyridin-1(2H)-yl]ethyl}benzoate 
• 1201818-12-3 tert-butyl 4-{2-[6-{[(tert-butoxycarbonyl)(4-ethylpyridin-2-yl)amino]methyl}-3,5-dichloro-2-oxopyridin-1(2H)-yl]ethyl}benzoate 
• 1201823-05-3 methyl 4-[2-(6-methyl-2-oxo-5-phenylpyridin-1(2H)-yl)ethyl]benzoate 
• 1201818-21-4 4-(2-{3,5-dichloro-6-[(6-ethoxy-2,3-dihydro-1H-indol-1-yl)methyl]-2-oxopyridin-1(2H)-yl}ethyl)benzoic acid 

Relevant academic research and scientific papers

PYRIDONE COMPOUND

[Problems] A useful compound which can be used as a pharmaceutical, in particular, an agent for treating peripheral arterial occlusive disease is provided. [Means for Solution] The present inventors have conducted extensive studies on EP4 receptor agonist

PYRIDONE COMPOUND

The present inventors have conducted extensive studies on an EP4 receptor agonist, and as a result, found that a novel pyridone compound characterized in that the 1-position in the pyridone ring is substituted with a group having an acidic group such as a